Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06618391
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-08
Brief Title:
Local Injection and Systemic Therapy in the Treatment of NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Envafolimab and Recombinant Human Endostatin and Recombinant Human Adenovirus Type 5 Intratumor Local Injection Combined With Systemic Therapy in Patients With Advanced NSCLC a Prospective Exploratory Phase II Clinical Study Tudy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancerNSCLC
Detailed Description:
This study is a prospective exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancerNSCLC
Patients with pathologically confirmed unresectable locally advancedadvanced NSCLC with atelectasis were screened and eligible subjects were randomized to receive local intratumoral injection of envolumabEndostarrecombinant human adenovirus type 5 H101 combined with systemic therapy after signing informed consent
Patients with pathologically confirmed unresectable locally advancedadvanced NSCLC with atelectasis were screened and eligible subjects were randomized to receive local intratumoral injection of envolumabEndostarrecombinant human adenovirus type 5 H101 combined with systemic therapy after signing informed consent
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None